

PREVENTION OF A FIRST STROKE BY TRANSFUSIONS IN CHILDREN WITH SICKLE CELL ANEMIA AND ABNORMAL RESULTS ON TRANSCRANIAL DOPPLER ULTRASONOGRAPHY

ROBERT J. ADAMS, M.D., VIRGIL C. MCKIE, M.D., LEWIS HSU, M.D., PH.D., BEATRICE FILES, M.D., ELLIOTT VICHINSKY, M.D., CHARLES PEGELOW, M.D., MIGUEL ABBOD, M.D., DIANNE GALLAGHER, M.S., ABDULLAH KUTLAR, M.D., FENWICK T. NICHOLS, M.D., DUANE R. BONDS, M.D., AND DONALD BRAMBILLA, PH.D.

ABSTRACT

Background Blood transfusions prevent recurrent stroke in children with sickle cell anemia, but the value of transfusions in preventing a first stroke is unknown. We used transcranial Doppler ultrasonography to identify children with sickle cell anemia who were at high risk for stroke and then randomly assigned them to receive standard care or transfusions to prevent a first stroke.

Methods To enter the study, children with sickle cell anemia and no history of stroke had to have undergone two transcranial Doppler studies that showed that the time-averaged mean blood-flow velocity in the internal carotid or middle cerebral artery was 200 cm per second or higher. The patients were randomly assigned to receive standard care or transfusions to reduce the hemoglobin S concentration to less than 30 percent of the total hemoglobin concentration. The incidence of stroke (cerebral infarction or intracranial hemorrhage) was compared between the two groups.

Results A total of 130 children (mean [\pm SD] age, 8.3 ± 3.3 years) were enrolled; 63 were randomly assigned to receive transfusions, and 67 to receive standard care. At base line, the transfusion group had a slightly lower mean hemoglobin concentration (7.2 vs. 7.6 g per deciliter, $P=0.001$) and hematocrit (20.4 vs. 21.7 percent, $P=0.002$). Ten patients dropped out of the transfusion group, and two patients crossed over from the standard-care group to the transfusion group. There were 10 cerebral infarctions and 1 intracerebral hematoma in the standard-care group, as compared with 1 infarction in the transfusion group — a 92 percent difference in the risk of stroke ($P<0.001$). This result led to the early termination of the trial.

Conclusions Transfusion greatly reduces the risk of a first stroke in children with sickle cell anemia who have abnormal results on transcranial Doppler ultrasonography. (N Engl J Med 1998;339:5-11.)

©1998, Massachusetts Medical Society.

STROKE occurs by the age of 20 in about 11 percent of patients with sickle cell anemia.¹⁻³ The most frequent cause of brain infarction in these patients is blockage of the intracranial internal carotid and middle cerebral arteries.^{4,5} These lesions can be detected by transcranial Doppler ultrasonography^{6,7} because blood-flow velocity is inversely related to arterial diameter. High blood-

flow velocity has been correlated with stenosis on angiography,⁷ increased cerebral blood flow,⁸ and subsequent stroke in children with sickle cell anemia.^{9,10}

In a cohort of 315 children^{9,10} with no history of stroke, the risk of a stroke increased significantly with increasing velocity of blood flow in the internal carotid artery or middle cerebral artery. This finding is the basis of our primary stroke-prevention trial in children with sickle cell anemia. Blood transfusion was used because it is highly effective in reducing the risk of recurrent stroke in sickle cell anemia.^{11,12} The Stroke Prevention Trial in Sickle Cell Anemia tested the hypothesis that periodic blood transfusion, with reduction of the hemoglobin S concentration to less than 30 percent of the total hemoglobin concentration, would lower the risk of stroke by 70 percent as compared with the risk associated with standard care.¹³

From the Departments of Neurology (R.J.A., E.T.N.), Pediatric Hematology and Oncology (V.C.M.), and Medicine (A.K.), Medical College of Georgia, Augusta; the Sickle Cell Center, Emory University School of Medicine, Atlanta (L.H.); the Department of Pediatric Hematology and Oncology, East Carolina University School of Medicine, Greenville, N.C. (B.F.); the Department of Hematology and Oncology, Children's Hospital Oakland, Oakland, Calif. (E.V.); the Sickle Cell Center, University of Miami School of Medicine, Miami (C.P.); the Pediatric Sickle Cell Program, Medical University of South Carolina, Charleston (M.A.); the New England Research Institutes, Watertown, Mass. (D.G., D.B.); and the National Heart, Lung, and Blood Institute, Bethesda, Md. (D.R.B.). Address reprint requests to Dr. Adams at the Department of Neurology, Medical College of Georgia, 1467 Harper St., HB-2060, Augusta, GA 30912-3200.

Other authors were Gerald Woods, M.D. (Department of Hematology and Oncology, Children's Mercy Hospital, Kansas City, Mo.), Nancy Olivieri, M.D. (Department of Hematology and Oncology, Hospital for Sick Children, Toronto), Catherine Driscoll, M.D. (Department of Hematology and Oncology, Children's National Medical Center, Washington, D.C.), Scott Miller (Pediatric Sickle Cell Program, State University of New York Health Science Center at Brooklyn, Brooklyn), Winfred Wang, M.D. (Department of Hematology and Oncology, St. Jude Children's Research Hospital, Memphis, Tenn.), Anne Hurllett, M.D. (Department of Pediatric Hematology, Columbia-Presbyterian Medical Center, New York), Charles Scher, M.D. (Department of Pediatric Hematology and Oncology, Tulane University Medical School, New Orleans), Brian Berman, M.D. (Department of Pediatric Hematology and Oncology, Rainbow Babies and Children's Hospital, Cleveland), Elizabeth Carl, B.A., and Anne M. Jones, R.N. (Department of Neurology, Medical College of Georgia, Augusta), E. Steve Roach, M.D. (Department of Pediatric Neurology, University of Texas Southwestern Medical Center, Dallas), Elizabeth Wright, Ph.D. (New England Research Institutes, Watertown, Mass.), Robert A. Zimmerman, M.D. (Department of Neuroradiology, Children's Hospital of Philadelphia, Philadelphia), and Myron Waclawiw, Ph.D. (National Heart, Lung, and Blood Institute, Bethesda, Md.).

METHODS

Subjects

Patients who were 2 to 16 years of age and who had been given a diagnosis of sickle cell anemia or sickle β^0 thalassemia were eligible for screening by transcranial Doppler ultrasonography. Patients were excluded from the study if they had a history of stroke, had an indication for or contraindication to long-term transfusion, were receiving other treatments that affected the risk of stroke, were infected with the human immunodeficiency virus (HIV), had been treated for seizures, were pregnant, or had a serum ferritin concentration above 500 ng per milliliter. Informed consent was obtained from the patients' parents or guardians.

Transcranial Doppler Ultrasonography

Transcranial Doppler ultrasonographers were trained to follow a protocol similar to that used in adults,⁶ but modified for children with sickle cell anemia.^{13,14} Examiners used identical equipment (2-MHz pulsed Doppler ultrasonograph, model EME TC 2000, Nicolet, Madison, Wis.) and recorded the highest time-averaged mean blood-flow velocity in 2-mm increments in the middle cerebral artery (at three points), the distal internal carotid artery, the anterior and posterior cerebral arteries, and the basilar artery. Experts at the Medical College of Georgia who were unaware of the patients' conditions read the results and categorized them as normal, conditional, abnormal, or inadequate. If all velocities were less than 170 cm per second, the results were considered to be normal. A velocity of at least 170 but less than 200 cm per second was considered to be conditional. To be considered abnormal, blood-flow velocity had to be at least 200 cm per second in either the internal carotid artery or the middle cerebral artery. To enter the study, each patient had to have abnormal results on two transcranial Doppler studies. The use of a permuted block design approximately balanced treatment assignment within centers. The cutoff point was taken from pilot studies^{9,10,13} in which a flow rate of 200 cm per second was associated with a 40 percent risk of stroke within three years.

Treatment Protocol

The base-line evaluation included magnetic resonance imaging (MRI)¹³; a structured neurologic examination; a physical examination; medical history taking; a complete blood count with differential, platelet, and reticulocyte counts; quantitative hemoglobin analysis by high-performance liquid chromatography¹⁵; determination of the sickle-cell gene haplotype; mapping of the α -globin gene; liver-function tests (alanine aminotransferase, aspartate aminotransferase, γ -glutamyltransferase, lactate dehydrogenase, and bilirubin); serum ferritin measurement; and assessment for prior infection with hepatitis B and C viruses.

Concomitant care included penicillin prophylaxis, pneumococcal vaccination, folic acid supplementation, surgery, and treatment of acute illness, including the use of transfusion when needed for transient episodes but excluding the use of hydroxyurea or antisickling agents. Vaccination against hepatitis B was required if appropriate.

Patients were randomly assigned to receive either standard care or transfusions. The goal in using transfusions was to reach the target hemoglobin S concentration (<30 percent of total hemoglobin) within a period of 21 days without exceeding a hemoglobin concentration of 12 g per deciliter and a hematocrit of 36 percent, measured before transfusion. Exchange or simple transfusions were allowed. Red cells that were negative for hemoglobin S and depleted of leukocytes were delivered in a volume of approximately 10 to 15 ml per kilogram of packed cells per transfusion. The concentration of hemoglobin S was determined by high-performance liquid chromatography at the Medical College of Georgia.¹⁵ Blood was matched for the ABO blood group, the Kell (K) blood group, and Rh antigens C, D, and E.

Once their hemoglobin S concentration was 30 percent of total hemoglobin or less, children received transfusions every three to

four weeks. Adverse reactions to transfusion including hemolytic, allergic, and febrile reactions; anaphylaxis; circulatory overload; hypertension; and hemoglobinuria and alloimmunization were recorded. The complete blood count, platelet and reticulocyte counts, and measurements of hemoglobin S, ferritin, and liver enzymes were performed quarterly. Tests for antibodies to HIV, human T-cell lymphotropic virus type I (HTLV-I), hepatitis B surface antigen, and hepatitis C were performed at base line and at the end of the study.

End Points

The protocol was intended to identify all neurologic events. A panel of physicians with no knowledge of the children's treatment assignments who were not affiliated with the study centers determined whether an event was a stroke. The primary end points were cerebral infarction and intracranial hemorrhage. Focal symptoms consistent with the occurrence of a cerebral infarction or an intracerebral hematoma were required unless the presentation suggested a diagnosis of subarachnoid hemorrhage. MRI studies obtained after the events were compared with those obtained at base line and annually thereafter. In the absence of supporting MRI findings, clear and compelling clinical evidence of a stroke was required. Transient symptoms were included if changes consistent with the occurrence of stroke were evident on MRI.

Statistical Analysis

Base-line characteristics including age; sex; concentrations of hemoglobin S, fetal hemoglobin, and total hemoglobin; blood-flow velocity on the confirmatory transcranial Doppler study (the second of two qualifying examinations with abnormal results); and the presence or absence of ischemic lesions at base line on MRI were compared by the t-test or chi-square test. The incidence of stroke was compared between the groups with an unadjusted proportional-hazards regression model¹⁶ according to the intention to treat. The severity of stroke was estimated at hospital discharge with the modified Rankin scale.¹⁷ Four interim analyses and one final analysis were planned, with the Lan-DeMets approximation of the O'Brien-Fleming stopping boundary.¹³ The date of the first analysis was changed from 20 months to 14 months after recruitment began.

The data and safety monitoring board was appointed by the National Heart, Lung, and Blood Institute to approve the protocol and consent procedures, oversee data collection and patient safety, and recommend discontinuation of the trial if serious safety or ethical issues arose. The board consisted of two pediatric hematologists, a pediatric neurologist, two statisticians, two neuroradiologists, and one medical ethicist.

RESULTS

Screening began in January 1995 and ended in November 1996 after 3929 transcranial Doppler studies had been performed on 1934 children. The base-line rate of abnormal results for all children was 9.7 percent and was higher among children 2 to 8 years of age (120 of 1117, or 10.7 percent) and 9 to 12 years of age (47 of 502, or 9.4 percent) than among those who were 13 to 16 years of age (20 of 315, or 6.3 percent) ($P=0.03$ by the Mantel-Haenszel test for trend). Seventy-nine children who had normal results at the first screening subsequently had abnormal results. Of 266 children with abnormal results on one Doppler study, 242 had at least one subsequent examination, the results of which were also abnormal in the cases of 206 children (85 percent). Of these 206 patients, who were eligible for the study because they had abnormal re-

sults on two Doppler examinations, 14 were found to be ineligible for other reasons: 5 had high serum ferritin concentrations, 4 declined to undergo HIV testing, 1 had a stroke before randomization, 1 was unable to start treatment, 1 had a contraindication to transfusion, and in the case of 2 others an indication for transfusion developed after the Doppler studies. Sixty-two patients declined to undergo randomization or were not enrolled by the investigators: 35 expressed reluctance to receive transfusions (34 children) or standard care (1); 17 were not enrolled because of investigators' concern about compliance, and 10 others did not give a reason for refusing to participate. The patients who were not enrolled did not differ substantially from those who were enrolled in terms of age, sex, blood-flow velocity, or hematologic characteristics.

We enrolled 130 children (60 boys and 70 girls), including five pairs of siblings, in the study: 63 were randomly assigned to receive transfusions, and 67 to standard care. The status of all but one child was known when the trial was halted in September 1997. One patient with a serum ferritin concentration of more than 500 ng per milliliter was approved for entry because a liver biopsy showed low iron stores.

Base-line hemoglobin and hematocrit values were slightly lower in the transfusion group (Table 1). The blood-flow velocity recorded during the confirmatory transcranial Doppler study and the prevalence of abnormalities on MRI did not differ significantly between the two groups.

Ten patients dropped out of the transfusion group at the outset or after 2 to 23 months. One patient had multiple alloantibodies, one was found to be ineligible because the results of only one Doppler study were abnormal (the results of the other were conditional), four had problems with compliance, and four dropped out for unspecified reasons. One of these 10 patients was subsequently lost to follow-up. Two patients crossed over from the standard-care group to the transfusion group, one on day 2 because the base-line MRI showed a subacute intracerebral hematoma. MRI findings and the patient's history of headache 31 days before the test suggested that the hematoma had occurred before randomization, but the event was counted as occurring on day 2. The other patient started receiving transfusions after 12 months because of leg ulcers.

The 63 patients in the transfusion group received a total of 1521 transfusions. Most were simple trans-

TABLE 1. BASE-LINE CHARACTERISTICS OF THE PATIENTS.*

CHARACTERISTIC	TOTAL (N=130)	TRANSFUSION (N=63)	STANDARD CARE (N=67)	P VALUE
Male sex — no. of patients (%)	60 (46)	31 (49)	29 (43)	0.50†
Age — yr	8.3±3.3	8.2±3.5	8.4±3.2	0.71
Hemoglobin — g/dl‡	7.4±0.8	7.2±0.8	7.6±0.7	0.001
Hematocrit — %‡	21.1±2.3	20.4±2.4	21.7±2.1	0.002
White-cell count — ×10 ⁻³ /mm ³ ‡	12.4±3.6	12.5±3.7	12.2±3.4	0.66
Reticulocyte count — %‡	12.8±4.5	12.5±4.8	13.2±4.2	0.41
Platelet count — ×10 ⁻³ /mm ³ §	395±101	388±115	402±87	0.44
Hemoglobin S — %‡	87±9	87±10	87±7	0.66
Fetal hemoglobin — %‡	8.7±5.1	8.0±5.2	9.4±5.0	0.14
Ferritin — ng/ml‡	153±130	164±155	142±101	0.35
Four α-globin genes — no. of patients (%)¶	109 (84)	49 (78)	60 (91)	0.075
Systolic blood pressure — mm Hg‡	107±10	106±9	109±11	0.19
Diastolic blood pressure — mm Hg‡	55±10	55±10	56±10	0.54
Blood-flow velocity — cm/sec				
Mean	223±28	223±27	223±28	0.93
Median	213	214	212	
Lesions on initial MRI — no. of patients (%)**	44 (35)	19 (31)	25 (38)	0.39†

*Plus-minus values are means ±SD. P values are for the differences between subgroups. Except as noted, Student's t-test was used.

†The chi-square test was used.

‡Data were missing on one patient in the transfusion group.

§Data were missing on one patient in each group.

¶Data were missing on one patient in the standard-care group.

||Fisher's exact test was used.

**Data were missing on one patient in each group. In addition, one patient in the standard-care group who had left frontal hemorrhage at base line was excluded.

fusions (63 percent), 12 percent were exchange transfusions, and 25 percent were a combination of simple and exchange transfusions. The mean (\pm SD) serum ferritin concentration in the transfusion group increased from 164 ± 155 ng per milliliter at base line to 1804 ± 773 ng per milliliter at 12 months (range, 945 to 5773 in 51 patients) and 2509 ± 974 ng per milliliter at 24 months (range, 912 to 5702 in 23 patients). In 10 patients evidence of alloimmunization against red-cell antigens developed; 4 had antibodies to E or K antigens, and 6 to other red-cell antigens. There were 16 mild reactions to blood products or transfusion procedures in 12 patients. In no patient did evidence of hepatitis C infection develop, and all 100 children who were tested were negative for antibodies against HIV and HTLV-I. Central venous catheters were implanted in five children.

The mean interval between transfusions was 25 ± 8 days. After the exclusion of the first 28 days after randomization, we found that 46 patients (78 percent of those who received transfusions) had at least one hemoglobin S measurement that exceeded 30 percent of the total hemoglobin concentration. The 143 episodes in which the target was exceeded were usually isolated and minor: in 70 cases (49 percent) values were in the range of 30.0 to 34.9 percent, in 31 cases (22 percent) values were in the range of 35.0 to 39.9 percent, and in 42 cases (29 percent) values were 40.0 percent or higher.

Twenty-nine potential strokes were assessed in 23 patients. Eleven children in the standard-care group and one child in the transfusion group had a stroke (Table 2). None of the patients who crossed over either to or from the transfusion group had a stroke. There were no deaths. Ten of these strokes were reported at the time symptoms occurred, and one was discovered at a quarterly visit. One of the strokes was an intracerebral hematoma and was discovered on the base-line MRI. When the child with the intracerebral hematoma was included in the primary analysis, the difference between treatments was significant ($P<0.001$), with the risk of stroke being 92 percent lower in the transfusion group. When this patient was excluded from the analysis (Fig. 1), the risk of stroke in the transfusion group was still 91 percent lower ($P=0.002$). In the standard-care group the rate of stroke was 10 percent per year. The single stroke in the transfusion group occurred after 26 months. The stroke-free survival curve in the transfusion group in Figure 1 shows a relatively large drop (from 100 percent to 92 percent) because only 13 patients had been followed for 26 months when the study was halted. Because of the high rate of stroke in the standard-care group and the significant effect of transfusion found at the second interim analysis, the data safety and monitoring board recommended that the trial be stopped 16 months before the planned date of December 1998 so that

TABLE 2. LENGTH OF FOLLOW-UP AND NUMBER OF PRIMARY EVENTS.

VARIABLE	TOTAL (N=130)	TRANSFUSION (N=63)	STANDARD CARE (N=67)
Follow-up (mo)			
Total	2550	1321	1229
Median	21.1	22.2	18.3
Mean \pm SD	19.6 ± 6.5	21.0 ± 5.7	18.3 ± 7.0
No. of strokes	12	1	11
Cerebral infarction	11	1	10
Intracerebral hematoma	1	0	1




Figure 1. Kaplan-Meier Estimate of the Probability of Not Having a Stroke among Patients Receiving Long-Term Transfusion and Patients Receiving Standard Care.

The P value was calculated by proportional-hazards regression analysis. Tick marks indicate the lengths of observation of patients who did not have a stroke. One patient in the standard-care group who had an intracerebral hematoma was excluded from the analysis.

transfusion could be offered to children in the standard-care group.

The 11 patients with cerebral infarction presented with hemiparesis, but weakness had resolved by the time of the neurologic examination. Of these 11 patients, 10 were hospitalized. At discharge, two had major disability, five had mild-to-moderate disability, two had symptoms but no disability, and one was asymptomatic. All infarctions were in the carotid circulation, and MRI showed new or larger lesions in the symptomatic hemisphere in all but one patient

TABLE 3. CHARACTERISTICS OF THE 11 PATIENTS WHO HAD CEREBRAL INFARCTIONS.*

PATIENT No.	AGE AT ENTRY	Hb S/FETAL Hb AT ENTRY	BLOOD-FLOW VELOCITY†		BASE-LINE MRI LESIONS‡		TIME FROM STUDY ENTRY TO STROKE	SYMPTOMS	POST-STROKE MRI LESIONS	
			RIGHT	LEFT	RIGHT	LEFT			RIGHT	LEFT
	yr	%	cm/sec				mo			
1	15	96/2	251	257	Yes	Yes	14	Left hemiparesis, dysarthria	Yes (worse)	Yes (new)
2	2	78/21	216	229	No	No	24	Right hemiparesis, aphasia	No	Yes (new)
3	3	82/16	148	201	Yes	Yes	4	Right hemiparesis, seizure	Yes (new)	Yes (new)
4	9	92/6	202	204	Yes	Yes	21	Right hemiparesis, aphasia	Yes	Yes (new)
5	7	94/3	246	264	Yes	Yes	1	Left hemiparesis, dysarthria	Yes (new)	Yes (new)
6	8	81/16	170	244	Yes	No	14	Right hemiparesis, aphasia	Yes	Yes (new)
7	7	89/9	287	189	No	No	15	Left hemiparesis, dysarthria	Yes (new)	Yes (new)
8	11	91/7	219	319	Yes	No	4	Right hemiparesis, aphasia	Yes	Yes (new)
9	12	89/8	217	201	Yes	Yes	18	Left hemiparesis, dysarthria	Yes (worse)	Yes
10	6	91/6	203	186	No	No	9	Left hemiparesis	Yes (new)	Yes (new)
11	5	76/3§	225	156	No	No	26	Left hemiparesis, dysarthria, facial weakness	No	No

*One patient with left frontal hemorrhage at base line was excluded. Hb denotes hemoglobin, and MRI magnetic resonance imaging.

†Values are the highest time-averaged mean velocity recorded in the middle cerebral artery or internal carotid artery during the confirmatory Doppler study.

‡Signs of atrophy were excluded.

§Patient 11, who was assigned to the transfusion group, had received a transfusion 11½ weeks before entering the study.

(Table 3). Base-line results of transcranial Doppler studies were abnormal on the side on which the stroke occurred, but the results were also abnormal on the opposite side in six patients. Of seven patients with abnormalities on base-line MRI, two subsequently had a stroke in the hemisphere opposite to the base-line lesion.

We attempted to determine whether considering the results of the base-line MRI and hemoglobin and hematocrit measurements added to the ability of transcranial Doppler studies to predict stroke. For this purpose we analyzed the standard-care group, excluding the patient with hematoma. The analysis was confounded by a correlation between results of the MRI and Doppler studies. Patients with a blood-flow velocity of 240 cm per second or higher were more likely to have MRI lesions than patients with velocities of 200 to 239 cm per second (9 of 15 patients, or 60 percent, vs. 16 of 51 patients, or 31 percent; $P=0.045$ by the chi-square test). Proportional-hazards regression showed that the results of transcranial Doppler and MRI studies were significant predictors of stroke when considered separately ($P=0.010$ and $P=0.038$, respectively), but hemo-

globin ($P=0.12$) and hematocrit ($P=0.12$) values were not. Only the transcranial Doppler study was significant when both MRI and Doppler studies were considered together ($P=0.08$ and $P=0.03$, respectively).

DISCUSSION

The current trial was made possible by the availability of transcranial Doppler ultrasonography, which is a safe and relatively inexpensive technique with reproducible results.¹⁸ The high rate of stroke in children with abnormal results on transcranial Doppler studies and the marked efficacy of transfusion support the clinical application of the strategy we used. The two randomized groups in this trial were balanced, except for base-line hemoglobin and hematocrit values. If this small difference had any effect, it would have diminished the effect of transfusion, because lower hemoglobin concentrations have been associated with higher risk of stroke.³

There were no strokes among children in whom the targeted decrease in hemoglobin S (to ≤ 30 percent of the total hemoglobin concentration) was occasionally not met, suggesting that brief periods of

noncompliance with the transfusion program do not negate the benefits of prior treatment. The mechanism by which transfusion prevents stroke is not known. A reduction in hemoglobin S or an increase in total hemoglobin could have beneficial effects on cerebral vessels or interactions between erythrocytes and endothelial cells,¹⁹ but other factors may be involved. The rate of alloimmunization was lower than in other studies in which phenotypic matching was not routine.²⁰ The number of patients who discontinued receiving transfusions (10 of 63) and the frequency of missed transfusions demonstrate the difficulties with long-term transfusion therapy. The resulting rapid rise in ferritin concentrations reinforces the need to prevent iron accumulation. Chelation, although effective, involves long-term treatment, and thus compliance is a problem.²¹

It is unclear how long transfusion should be continued as a means of preventing stroke in children with sickle cell anemia. The incidence of a first stroke is highest between the ages of 2 and 5 years (1.02 per 100 patient-years), falling to 0.79 between 6 and 9 years of age, and to 0.41 between 10 and 19 years of age.³ The cohort study at the Medical College of Georgia showed that the risk of stroke was approximately 40 percent in the three years following abnormal results on transcranial Doppler studies, but it is unclear how long the risk remains elevated after this time without treatment.¹⁰ In the current trial, the risk of stroke was 10 percent per year without treatment.

The duration of the period of elevated risk is a crucial issue in deciding whether to start or continue transfusions and whether to consider bone marrow transplantation.²² If future studies show that transcranial Doppler ultrasonography can be used to predict the long-term risk of stroke, then the use of higher-risk therapies such as bone marrow transplantation might be reasonable. However, if treatment is needed for only a relatively short period, then the risks of bone marrow transplantation may not be justified. Alternative ways of reducing the concentrations of hemoglobin S^{23,24} and the use of hydroxyurea²⁵ as a primary means of prevention have not been studied. Prophylactic transfusion is an important first step, but the long-term benefit of this approach may be limited by the cost and complications of transfusion.

It is likely that the risk of stroke varies among children with abnormal results on transcranial Doppler ultrasonography, but this trial was not designed to identify high-risk subgroups. Our cohort had twice as high a prevalence of MRI abnormalities as the children in the Cooperative Study of Sickle Cell Disease,²⁶ who were not selected on the basis of the results of transcranial Doppler ultrasonography. The higher prevalence may indicate a causal relation or the coincidence of unrelated risk factors. Our sub-

group analysis showed that, among patients with abnormal results on Doppler studies, higher blood-flow velocities indicate a higher risk of stroke. The results of MRI did not add significantly to the predictive power of the ultrasonographic results, but this finding is not conclusive because of the small number of patients with strokes.

Some of the children with stroke had minor or transient motor findings. This is typical of children with sickle cell anemia who have a stroke, but more extensive testing often shows serious neuropsychological deficits.²⁷ The patient in the transfusion group who had a stroke did not have new MRI findings. Although atypical, such findings have been reported.²⁸

Any clinical application of our findings requires an approach to transcranial Doppler screening that is similar to the one we used. Our data were obtained using similar machines and software and specially certified examiners. The risk was estimated from a single value for blood-flow velocity that represented the highest velocity in either the middle cerebral artery or the internal carotid artery. Since velocity may vary with the depth and the probe angle used, even when the sample volume is increased by increments of 2 mm, careful attention to technique is required so that the segment with the highest velocity is recorded. Examiners must be trained in this technique. We recommend evaluating all vessels in the circle of Willis to ensure anatomical orientation. A confirmatory transcranial Doppler study is required to verify that blood-flow velocity is persistently high.

The optimal frequency of transcranial Doppler screening remains to be established. Techniques vary, and comparative studies are needed to determine whether transcranial Doppler imaging devices^{29,30} that use different signal-acquisition paradigms provide velocity data comparable to those obtained in our study. Other tests, including MRI and magnetic resonance angiography, cannot be substituted for transcranial Doppler ultrasonography because there are currently insufficient data on the long-term risk of stroke associated with abnormalities detected by these tests.

The decision to initiate transfusion on the basis of our results should be made only after careful consideration of the risks and benefits. Blood should be matched for ABO, C, D, E, and K antigens, and the transfusions should be handled by a facility with experience with transfusion and its complications. Problems with venous access and compliance can be expected. The complications and costs of transfusion are considerable, but they are predictable and manageable. These issues must be weighed against the risk of irreversible brain damage due to stroke, the severity of which cannot be predicted. The strategy that we tested offers a way of lessening the burden of this important complication of sickle cell anemia.

Supported by Cooperative Agreements (U10 HL 52193 and U10 HL 52016) with the National Heart, Lung, and Blood Institute.

We are indebted to the following persons for their contributions to this study: data safety and monitoring board appointed by the National Heart, Lung, and Blood Institute — Howard Pearson, M.D., Darleen Powars, M.D., Donald Younkin, M.D., Taber El-Gammal, M.D., Joanna Seibert, M.D., Lemuel Moye, M.D., Ph.D., Mark Espeland, Ph.D., Robert Murray, M.D.; New England Research Institutes — Sonja McKinlay, Ph.D., Susan Hagner, M.F.A., Steve Weiner, M.S., Sarah Estow, B.A., Maria Yelle, B.A.; research coordinators — Kim Brock, R.N., Eldrida Carter, B.S., Kathy Chiarucci, R.N., Mary Debarr, R.N., Pansy Feron, P.A.-C., N.P.H., Sylvia Harris, R.N., Laura Hoey, R.N., Kathy Jacques, R.N., Lisa Kuisel, R.N., Norma Lewis, R.N., Ramona Lindsey, R.N., Brenda Martin, P.N.P., Claire McMechan, R.N., Maria Muracca, R.N., Kathy Rey, P.A., Greta Roath, Ekua Hackney-Stephens, P.N.P., Linda Sumter, Aimee Talbot, R.N., Gayle Taplin, R.N., Carol Whittle, M.S.N., Patrice Woods, P.N.P.; Medical College of Georgia — Jeanette Harbin, B.S., Leslie Holley, B.S., Brenda Jackson, B.S., Ferdane Kutlar, M.D., Bonnie Miller, M.B.A., Nadine Odo, B.A., Mary Sahn, B.S., Judi Schweitzer, Amy Winstead, B.B.A.; Pediatric Sickle Cell Clinic; Thomas Swift, M.D.; and the Department of Neurology: Frank Allen, Katie Allen, Michael Beasley, B.S., Archana Ejanthkar, B.S., Eric Houston, B.A., David Hunter, B.A., Judy Luden, Jeff Ottenlips, Sam Trocio, Caterina Hernandez, B.S., Kathleen McKie, M.D., Anne Marie McMorrow-Touby, M.D., Ronald Perry, Ph.D., Jacqueline Bello, M.D., Naomi Luban, M.D., Franklin Moser, M.D., Louis Caplan, M.D., Dana DeWitt, M.D., Anthony Riela, M.D., Paul Babin, M.D., Joel Cure, M.D., Patricia Davis, M.D., Ramon Figueroa, M.D., Eric Gaensler, M.D., Wendy Hotson, M.D., Michael Kodroff, M.D., James Langston, M.D., Jonathan Lewin, M.D., Tae Rho, M.D., Glen Seidel, M.D., Curtis Sutton, M.D., Gilbert Vezina, M.D., Michelle Whitman, M.D., Majeed Al-Mateen, M.D., James Barfield, M.D., Abba Caragan, M.D., Richard Curless, M.D., Sergio Facchini, M.D., Frank Flemming, M.D., Ken Holden, M.D., Duane MacGregor, M.D., Jerome Murphy, M.D., Roger Packer, M.D., Yong Park, M.D., Arthur Rose, M.D., Curtis Sutton, M.D., Max Wiznitzer, M.D.; and the patients and their families.

REFERENCES

1. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. *Am J Med* 1978;65:461-71.
2. Adams RJ. Neurologic complications. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. *Sickle cell disease: scientific principles and clinical practice*. New York: Raven Press, 1994:599-621.
3. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. *Blood* 1998;91:288-94.
4. Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. *N Engl J Med* 1972;287:846-9.
5. Rothman SM, Fulling KH, Nelson JS. Sickle cell anemia and central nervous system infarction: a neuropathological study. *Ann Neurol* 1986; 20:684-90.
6. Aaslid R. Developments and principles of transcranial Doppler. In: Newell DW, Aaslid R, eds. *Transcranial Doppler*. New York: Raven Press, 1992:1-8.
7. Adams RJ, Nichols FT, Figueroa R, McKie V, Lott T. Transcranial Dop-

- pler correlation with cerebral angiography in sickle cell disease. *Stroke* 1992;23:1073-7.
8. Brass LM, Pavlakis SG, DeVivo D, Piomelli S, Mohr JP. Transcranial Doppler measurements of the middle cerebral artery: effect of hematocrit. *Stroke* 1988;19:1466-9.
9. Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. *N Engl J Med* 1992;326:605-10.
10. Adams RJ, McKie VC, Carl EM, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. *Ann Neurol* 1997;42:699-704.
11. Russell MO, Goldberg HI, Hodson A, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. *Blood* 1984;63:162-9.
12. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. *J Pediatr* 1995;126:896-9.
13. Adams RJ, McKie VC, Brambilla D, et al. Stroke prevention trial in sickle cell anemia. *Control Clin Trials* 1997;12:110-29.
14. Adams RJ, Litaker M, Nichols FT. Anemia and sickle cell disease. In: Babikian V, Wechsler LR, eds. *Transcranial Doppler ultrasonography*. St. Louis: Mosby-Year Book, 1993:160-71.
15. Bisse E, Wieland H. High-performance liquid chromatographic separation of human haemoglobins: simultaneous quantitation of foetal and glycated haemoglobins. *J Chromatogr* 1988;434:95-110.
16. Cox DR, Oakes D. *Analysis of survival data*. New York: Chapman & Hall, 1984.
17. Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. *Scott Med J* 1957;2:200-15.
18. Maeda H, Etani H, Handa N, et al. A validation study on the reproducibility of transcranial Doppler velocimetry. *Ultrasound Med Biol* 1990; 16:9-14.
19. Bunn HE. Pathogenesis and treatment of sickle cell disease. *N Engl J Med* 1997;337:762-9.
20. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease: the Cooperative Study of Sickle Cell Disease. *Blood* 1990;76:1431-7.
21. Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. *Blood* 1993;81:1109-23.
22. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. *N Engl J Med* 1996;335:369-76.
23. Miller ST, Jensen D, Rao SP. Less intensive long-term transfusion therapy for sickle cell anemia and cerebrovascular accident. *J Pediatr* 1992;120: 54-7.
24. Cohen AR, Martin MB, Silber JH, Kim HC, Ohene-Frempong K, Schwartz E. A modified program for prevention of stroke in sickle cell disease. *Blood* 1992;79:1657-61.
25. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. *N Engl J Med* 1995; 332:1317-22.
26. Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. *AJNR Am J Neuroradiol* 1996;17:965-72.
27. Ohene-Frempong K. Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. *Semin Hematol* 1991;28:213-9.
28. Alberts MJ, Faulstich ME, Gray L. Stroke with negative brain magnetic resonance imaging. *Stroke* 1992;23:663-7.
29. Seibert JJ, Miller SF, Kirby RS, et al. Cerebrovascular disease in symptomatic and asymptomatic patients with sickle cell anemia: screening with duplex transcranial Doppler US — correlation with MR imaging and MR angiography. *Radiology* 1993;189:457-66.
30. Verlhac S, Bernaudin F, Tortrat D, et al. Detection of cerebrovascular disease in patients with sickle cell disease using transcranial Doppler sonography: correlation with MRI, MRA and conventional angiography. *Pediatr Radiol* 1995;25:Suppl 1:S14-S19.

CORRECTION

Prevention of Stroke by Transfusions in Children with Sickle Cell Anemia

To the Editor: The results of the carefully conducted study by Adams et al. (July 2 issue)¹ of the value of transfusion in preventing strokes in children with sickle cell anemia and abnormal results on transcranial Doppler studies were impressive and promise to change approaches to the management of strokes in this disease. Adams et al. do not address the timing of the first transcranial Doppler study or the interval between studies. These important issues need to be addressed before a protocol based on transcranial Doppler ultrasonography can be universally applied.

A point requiring clarification is the total number of transcranial Doppler studies that the subjects underwent to determine their eligibility for the study. Only 79 children who had normal results at the first screening subsequently had abnormal results and thus would have required a third imaging examination. From the total number of transcranial Doppler studies (3929) performed on the 1934 patients in the study, it appears that an inordinately large number of patients had a third study. The authors should describe their criteria for a third study, since there is a potential for bias in this regard.

It is hardly surprising that transfusions prevented a first episode of stroke in children with sickle cell anemia. Since the late 1970s several studies^{2,3} have shown that maintaining hemoglobin S levels below 30 percent by means of transfusion can prevent recurrent strokes and largely eliminate the symptoms of the disease. However, the risks and difficulties of multiple transfusions, particularly given the need for long-term iron-chelation therapy, are formidable, as clearly stated in the accompanying editorial.⁴ The value of screening with transcranial Doppler ultrasonography in predicting a stroke is suggested by the finding of Adams et al. of a stroke rate of 10 per 102 patient-years in the untransfused group of study patients with repeatedly positive transcranial Doppler studies. This represents an increase by a factor of 10 over the results of previous studies, which showed a rate of 1.02 per 100 patient-years in a similar age group of unscreened children.⁵ It is disappointing that the authors did not present any data regarding the clinical outcome of the roughly 1700 patients who were found to have normal results on transcranial Doppler ultrasonography on one or more occasions. Ascertaining the prevalence of stroke in this cohort would have added considerable credibility to their conclusions about the value of screening with transcranial Doppler ultrasonography as a predictor of stroke.

Sharada A. Sarnaik, M.D.
Children's Hospital of Michigan
Detroit, MI 48201

References

1. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. *N Engl J Med* 1998;339:5-11.
2. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. *J Pediatr* 1995;126:896-899.
3. Sarnaik S, Soorya D, Kim J, Ravindranath Y, Lusher J. Periodic transfusions for sickle cell anemia and CNS infarction. *Am J Dis Child* 1979;133:1254-1257.
4. Cohen AR. Sickle cell disease – new treatments, new questions. *N Engl J Med* 1998;339:42-44.
5. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. *Blood* 1998;91:288-294.

The authors reply:

To the Editor: Dr. Sarnaik points out several important aspects of our study, which confirmed the ability of transcranial Doppler ultrasonography to identify a subgroup of children with a high risk of stroke and demonstrated that transfusion therapy significantly reduced the risk of stroke. The study was designed to investigate the efficacy of such treatment, but further research is needed to develop an optimal screening program.

The age at which the first screening study was performed in our study was two years, because stroke is not common in children younger than two years and younger patients often cannot lie quietly for the 30 to 40 minutes needed for the examination. The interval between studies and the total number of studies were determined by the screening algorithm, which based the interval between tests on the results of the first screening. It could be as short as a few weeks if the results of the first study were abnormal or as long as six to nine months if the initial results were normal, assuming the patient's compliance with the date arranged for the next test. Finally, children who were first screened late in the trial may not have had subsequent studies.

With such a design, described in detail elsewhere,¹ rescreening is biased toward patients who comply with the protocol of the study and who have more abnormal results. However, the rate of stroke in the standard-care group was sufficient to test the study question, and any screening bias was not detrimental to the trial.

We agree that the current state of knowledge of sickle cell disease is not optimal² and that better treatment for complications of the disease are being sought. However, our study provides solid information on the risks and benefits of a treatment that can be used today.

When Dr. Adams reviewed the galley proofs of the article, he made changes in the order of authorship without the permission of the four

authors involved and added a further author to the list. The correct list of authors and other authors is as follows:

Robert J. Adams, M.D., Virgil C. McKie, M.D., Lewis Hsu, M.D., Ph.D., Beatrice Files, M.D., Elliott Vichinsky, M.D., Charles Pegelow, M.D., Miguel Abboud, M.D., Gerald Woods, M.D., Nancy Olivieri, M.D., Catherine Driscoll, M.D., Scott Miller, M.D., and Donald Brambilla, Ph.D.

Other authors were Winfred Wang, M.D., Anne Hurllet, M.D., Charles Scher, M.D., Brian Berman, M.D., Elizabeth Carl, B.A., Fenwick T. Nichols, M.D., E. Steve Roach, M.D., Abdullah Kutlar, M.D., Elizabeth Wright, Ph.D., Robert A. Zimmerman, M.D., Dianne Gallagher, M.S., Myron A. Waclawiw, Ph.D., and Duane R. Bonds, M.D.

Lewis Hsu, M.D.

Emory University School of Medicine

Atlanta, GA 30303

Beatrice Files, M.D.

East Carolina University School of Medicine

Greenville, NC 27858

Robert J. Adams, M.D.

Medical College of Georgia

Augusta, GA 30912-3200

References

1. Adams RJ, McKie VC, Brambilla D. et al. Stroke Prevention Trial in Sickle Cell Anemia. *Control Clin Trials* 1997;19:110-129.
2. Cohen AR. Sickle cell disease – new treatments, new questions. *N Engl J Med* 1998;339:42-44.